Specialised Therapeutics to commercialize Incyte’s Opzelura in Australia
Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its partnership with Incyte Biosciences International, an affiliate of Incyte Corporation (INCY), to register, commercialize, and distribute ruxolitinib cream (marketed as Opzelura in the U.S. and EU) across Australia.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.